Sagredo Onintza, Ramos José A, Fernández-Ruiz Javier, Rodríguez María L López, de Miguel Rosario
Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, 28040, Madrid, Spain.
Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):313-7. doi: 10.1007/s00210-005-0026-1. Epub 2005 Dec 30.
Adult rats were subjected to chronic treatment with the cannabinoid agonist, Delta9-tetrahydrocannabinol, or with vehicle, and their brains used to analyze the contents of serotonin (5HT) and of its intraneuronal metabolite, 5-hydroxyindolacetic acid (5HIAA). 5HT and 5HIAA contents were not affected by chronic cannabinoid administration in most of the brain regions analyzed. We found a marked increase in 5HT contents in the frontal cortex that was accompanied by no changes in 5HIAA contents. This originated a decrease in 5HIAA/5HT ratio, which suggests a possible reduction in the activity of serotoninergic terminals reaching this cortical area. This effect was not seen after an acute injection of this cannabinoid. The relevance of these observations was that they occurred in a region where changes in serotoninergic transmission have been implicated in the development of depression; therefore, our data support the theory that the cannabinoid system might be a potential target for the treatment of this neuropsychiatric disease.
成年大鼠接受大麻素激动剂Δ⁹-四氢大麻酚或赋形剂的长期治疗,然后取其大脑分析血清素(5-羟色胺,5HT)及其神经元内代谢产物5-羟吲哚乙酸(5HIAA)的含量。在所分析的大多数脑区中,5HT和5HIAA的含量不受大麻素长期给药的影响。我们发现额叶皮质中5HT含量显著增加,而5HIAA含量没有变化。这导致5HIAA/5HT比值降低,这表明到达该皮质区域的血清素能终末的活性可能降低。急性注射这种大麻素后未观察到这种效应。这些观察结果的意义在于,它们发生在一个血清素能传递变化与抑郁症发展有关的区域;因此,我们的数据支持大麻素系统可能是治疗这种神经精神疾病的潜在靶点这一理论。